NEW YORK (360Dx) – BioMérieux said today it has signed a deal to commercialize Banyan Biomarkers' tests for diagnosing traumatic brain injuries (TBI).
Under the terms of the agreement, BioMérieux will make a $7 million equity investment in Banyan in exchange for rights to commercialize Banyan's TBI tests for global use as in vitro diagnostics on BioMérieux's VIDAS immunoassay platform.